13436 Federal Register / Vol. 74, No. 58 / Friday, March 27, 2009 / Notices 

Dated: March 20, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Office of 

the Chief Science Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. E9–6850 Filed 3–26–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Evaluating 

Locally-Developed (Homegrown) HIV 

Prevention Interventions for AfricanAmerican and Hispanic/Latino Men 

Who Have Sex With Men (MSM), 

Funding Opportunity Announcement 

(FOA) Number PA 09–007 and 

Operational Research To Improve the 

Implementation of Evidence-Based 

Interventions That Are Supported by 

the Diffusion of Effective Behavioral 

Interventions (DEBI) Project, FOA 

Number PA 09–008 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting. 

Time and Date: 8 a.m.–5 p.m., April 28, 

2009 (Closed). 

Place: Sheraton Gateway Hotel, Atlanta 

Airport, 1900 Sullivan Road, Atlanta, GA 

30337, Telephone (770) 997–1100. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the review, discussion, and 

evaluation of applications received in 

response to ‘‘Evaluating Locally-Developed 

(Homegrown) HIV Prevention Interventions 

for African-American and Hispanic/Latino 

Men Who Have Sex with Men (MSM), FOA 

Number PA 09–007,’’ and ‘‘Operational 

Research to Improve the Implementation of 

Evidence-Based Interventions that are 

Supported by the Diffusion of Effective 

Behavioral Interventions (DEBI) Project, FOA 

Number PA 09–008.’’ 

Contact Person for More Information: 

Gregory Anderson, M.P.H., M.S., Scientific 

Review Administrator, Strategic Science and 

Program Unit, Office of the Director, 

Coordinating Center for Infectious Diseases, 

CDC, 1600 Clifton Road, Mailstop E–60, 

Atlanta, GA 30333, Telephone: (404) 498– 

2275. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 20, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–6854 Filed 3–26–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Screening 

Targeted Populations To Interrupt Ongoing Chains of Transmission With 

Enhanced Partner Notification—The 

STOP Study, Funding Opportunity 

Announcement (FOA) Number PA 09– 

004 and Demonstration Project of 

Elective Adult Male Circumcision 

Conducted in Sexually Transmitted 

Disease (STD) Clinics in the United 

States, FOA Number PA 09–005 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting. 

Time and Date: 8 a.m.–5 p.m., April 27, 

2009 (Closed). 

Place: Sheraton Gateway Hotel, Atlanta 

Airport, 1900 Sullivan Road, Atlanta, GA 

30337, Telephone (770) 997–1100. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the review, discussion, and 

evaluation of applications received in 

response to ‘‘Screening Targeted Populations 

to Interrupt On-going Chains of Transmission 

with Enhanced Partner Notification—The 

STOP Study, FOA Number PA 09–004;’’ and 

‘‘Demonstration Project of Elective Adult 

Male Circumcision Conducted in Sexually 

Transmitted Disease (STD) Clinics in the 

United States, FOA Number PA 09–005.’’ 

Contact Person for More Information: 

Gregory Anderson, M.P.H., M.S., Scientific 

Review Administrator, Strategic Science and 

Program Unit, Office of the Director, 

Coordinating Center for Infectious Diseases, 

CDC, 1600 Clifton Road, Mailstop E–60, 

Atlanta, GA 30333, Telephone: (404) 498– 

2275. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 20, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–6859 Filed 3–26–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–2284–N] 

Deeming Notice for the College of 

American Pathologists (CAP) as an 

Accrediting Organization Under the 

Clinical laboratory Improvement 

Amendments of 1988 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

application of the College of American 

Pathologists (CAP) for approval as an 

accreditation organization for clinical 

laboratories under the Clinical 

Laboratory Improvement Amendments 

of 1988 (CLIA) program for all 

specialties and subspecialties. In this 

notice, we announce the approval and 

grant the CAP deeming authority for all 

CLIA specialties and subspecialties for a 

period of 6 years. We have determined 

that the CAP meets or exceeds the 

applicable CLIA requirements. 

DATES: Effective Date: This notice is 

effective from March 27, 2009 until 

March 27, 2015. 

FOR FURTHER INFORMATION CONTACT: Val 

Coppola, (410)786–3531. 

SUPPLEMENTARY INFORMATION: 

I. Background 

On October 31, 1988, the Congress 

enacted the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA), Public Law 100–578. CLIA 

amended section 353 of the Public 

Health Service Act. We issued a final 

rule implementing the accreditation 

provisions of CLIA on July 31, 1992 (57 

FR 33992). Under the CLIA program, 

CMS may grant deeming authority to an 

accreditation organization that accredits 

clinical laboratories if the organization 

meets certain requirements. An 

organization’s requirements for 

laboratories accredited under its 

program must be equal to or more 

stringent than the applicable CLIA 

program requirements in 42 CFR part 

493 (Laboratory Requirements). This 

requirement and others in subpart E of 

that part (Accreditation by a Private, 

mstockstill on PROD1PC66 with NOTICES